Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 180.
AMIPAQUE vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent